El bypass parcial del íleo para la hipercolesterolemia.

Same author

Novel effect of leptin on small intestine adaptation.

The Journal of surgical research·2001

Same author

Pharmacotherapy and growth factors in the treatment of short bowel syndrome.

Seminars in pediatric surgery·2001

Same author

GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.

Journal of pediatric surgery·2001

Same author

Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury.

Journal of pediatric surgery·2000

Same author

Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.

Journal of pediatric surgery·2000

Same author

Growth-factor enhancement of compromised gut function following massive small-bowel resection.

Pediatric surgery international·2000

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Videos de Experimentos Relacionados

El bypass parcial del íleo para la hipercolesterolemia.

Videos de Conceptos Relacionados

Novel effect of leptin on small intestine adaptation.

Pharmacotherapy and growth factors in the treatment of short bowel syndrome.

GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.

Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury.

Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.

Growth-factor enhancement of compromised gut function following massive small-bowel resection.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Videos de Experimentos Relacionados

El bypass parcial del íleo para la hipercolesterolemia.

Videos de Conceptos Relacionados

Artículos Relacionados

Novel effect of leptin on small intestine adaptation.

Pharmacotherapy and growth factors in the treatment of short bowel syndrome.

GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.

Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury.

Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.

Growth-factor enhancement of compromised gut function following massive small-bowel resection.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.